Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type: full-pipeline trial registry
1 of 2 indexed Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type: 2 US clinical trials tracked, 1 recruiting.
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Lapo Alinari, running 1 of these trials.
Enrollment posture brief
Registry condition refractory-diffuse-large-b-cell-lymphoma-activated-b-cell-type
OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Lapo Alinari
NCT05755087
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI)
NCT02443077
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Lapo Alinari sponsors the most Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type trials on record, review their full trial history before evaluating a specific study. See Lapo Alinari's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type condition card totals 2 registered trials; most-linked intervention Autologous Bone Marrow Transplantation; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.